The trial, run by the HIV Prevention Trials Network, enrolled more than 3,200 women who were not infected with HIV between the ages of 18 and 45 across seven countries in sub-Saharan Africa, areas of high HIV incidence. A total of 38 women contracted HIV, 34 who were given the pill compared to four who received the injection.
“We know that adherence to a daily pill regimen continues to be challenging, and an effective injectable product such as long-acting CAB is a very important additional HIV prevention option for them,” Sinead Delany-Moretlwe, MD, study chair, said in a news release.
Dr. Delany-Moretlwe directs research at Wits Reproductive Health and HIV Institute and is a research professor at the University of Witwatersrand in Johannesburg, South Africa.
An earlier study in cisgender men and transgender women found the injection to be more effective than the pill, but did not include cisgender women.
Further studies and reviews will be conducted before the injection becomes widely available.
More articles on public health:
US sees 6th day with 100K+ new cases; Eli Lilly’s antibody treatment gets emergency approval — 5 COVID-19 updates
24 states where COVID-19 is spreading fastest, slowest: Nov. 10
COVID-19, flu deaths increased in early October: 4 CDC findings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
